↓ Skip to main content
What is this page? Embed badge

Pharmacology and Therapeutics of Asthma and COPD

Overview of attention for book
Cover of 'Pharmacology and Therapeutics of Asthma and COPD'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 61 Pathogenesis of COPD and Asthma
  3. Altmetric Badge
    Chapter 62 Glucocorticosteroids
  4. Altmetric Badge
    Chapter 63 Drugs Affecting TRP Channels
  5. Altmetric Badge
    Chapter 64 β2 Agonists
  6. Altmetric Badge
    Chapter 65 Anti-IgE and Biologic Approaches for the Treatment of Asthma
  7. Altmetric Badge
    Chapter 66 Fixed-Dose Combination Inhalers.
  8. Altmetric Badge
    Chapter 67 Drug Delivery Devices for Inhaled Medicines
  9. Altmetric Badge
    Chapter 68 Muscarinic Receptor Antagonists
  10. Altmetric Badge
    Chapter 69 Bifunctional Drugs for the Treatment of Respiratory Diseases
  11. Altmetric Badge
    Chapter 70 Evaluation of New Drugs for Asthma and COPD: Endpoints, Biomarkers and Clinical Trial Design
  12. Altmetric Badge
    Chapter 71 Xanthines and Phosphodiesterase Inhibitors
  13. Altmetric Badge
    Chapter 72 Leukotriene Receptor Antagonists and Antiallergy Drugs
  14. Altmetric Badge
    Chapter 98 Glucocorticoids
Attention for Chapter 69: Bifunctional Drugs for the Treatment of Respiratory Diseases
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 X user

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
19 Mendeley
Summary X Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Bifunctional Drugs for the Treatment of Respiratory Diseases
Chapter number 69
Book title
Pharmacology and Therapeutics of Asthma and COPD
Published in
Handbook of experimental pharmacology, January 2016
DOI 10.1007/164_2016_69
Pubmed ID
27787715
Book ISBNs
978-3-31-952173-2, 978-3-31-952175-6
Authors

Clive Page, Mario Cazzola, Page, Clive, Cazzola, Mario

Abstract

Over the last decade, there has been a steady increase in the use of fixed dose combinations for the treatment of a range of diseases, including cancer, AIDS, tuberculosis and other infectious diseases. It is now evident that patients with asthma or chronic obstructive pulmonary disease (COPD) can also benefit from the use of fixed dose combinations, including combinations of a long-acting β2-agonist (LABA) and an inhaled corticosteroid (ICS), and combinations of LABAs and long-acting muscarinic receptor antagonists (LAMAs). There are now also "triple inhaler" fixed dose combinations (containing a LABA, LAMA and ICS) under development and already being made available in clinical practice, with the first such triple combination having been approved in India. The use of combinations containing drugs with complementary pharmacological actions in the treatment of patients with asthma or COPD has led to the discovery and development of drugs having two different primary pharmacological actions in the same molecule that we have called "bifunctional drugs". In this review we have discussed the state of the art of bifunctional drugs that can be categorized as bifunctional bronchodilators, bifunctional bronchodilator/anti-inflammatory drugs, bifunctional anti-inflammatory drugs and bifunctional mucolytic and anti-inflammatory drugs.

View on publisher site
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
 Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 16%
Student > Ph. D. Student 3 16%
Student > Bachelor 2 11%
Professor 2 11%
Student > Postgraduate 2 11%
Other 4 21%
Unknown 3 16%
Readers by discipline Count As %
Medicine and Dentistry 7 37%
Pharmacology, Toxicology and Pharmaceutical Science 2 11%
Social Sciences 2 11%
Nursing and Health Professions 1 5%
Agricultural and Biological Sciences 1 5%
Other 0 0%
Unknown 6 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2017.
All research outputs
#15,479,632
of 23,002,898 outputs
Outputs from Handbook of experimental pharmacology
#399
of 647 outputs
Outputs of similar age
#232,133
of 394,604 outputs
Outputs of similar age from Handbook of experimental pharmacology
#42
of 55 outputs
Altmetric has tracked 23,002,898 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 647 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 394,604 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.